Study Enrollment

Your details will not be published or shared.

Clinical Trial

ONT-380-206: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) with two approved drugs (capecitabine and trastuzumab) in patients with advanced breast cancer to find out what effects, good or bad, it may have.

Eligibility Criteria

  • Must be at least 18 years of age Must have a diagnosis of HER2+ breast cancer Must have adequate organ function Subject cannot have: Cardiopulmonary disease, uncontrolled infections

Contact Information

    Sandy Wall

    (706) 721-4330